Rosiglitazone-Associated Fractures in Type 2 Diabetes

Kahn, Steven E., Zinman, Bernard, Lachin, John M., Haffner, Steven M., Herman, William H., Holman, Rury R., Kravitz, Barbara G., Yu, Dahong +4 more·2008·Diabetes Care
DOI 10.2337/dc07-2270

Cited by (545)

Items 401–500 of 545

  1. Secondary Osteoporosis
    Gregory R. Emkey · 2018 · Elsevier eBooks
  2. Secondary osteoporosis
    Gregory R. Emkey · 2024 · Elsevier eBooks
  3. The Gene Network Correlation Analysis of Obesity to Type 1 Diabetes and Cardiovascular Disorders: An Interactome-Based Bioinformatics Approach
    Sharon Elaine D’Souza, Kanwal Khan, Khurshid Jalal, Muhammad Hassam, Reaz Uddin · 2023 · Molecular Biotechnology
  4. Structure and Function of Bone Marrow Adipocytes
    Francisco José Albuquerque de Paula, Clifford james Rosen · 2018 · Comprehensive physiology
  5. An update on diabetes related skeletal fragility
    Naiemh Abdalrahman, Suet Ching Chen, Jessie Ruijun Wang, S. Faisal Ahmed · 2015 · Expert Review of Endocrinology & Metabolism
  6. Response to Letter Regarding Article, “Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial”
    Richard G. Bach, Maria M. Brooks, M. Lombardero, SAUL M. GENUTH, Thomas W. Donner, Alan J. Garber, Laurence Kennedy, Ernest Scott Monrad, Rodica Pop‐Busui, Sheryl F. Kelsey et al. · 2014 · Circulation
  7. Translational Endocrinology & Metabolism: Metabolic Surgery Update
    DEL PRATO, STEFANO, Lebovitz HE · 2012 · Translational endocrinology & metabolism
  8. Recommendations on the effect of antidiabetic drugs in bone
    Pedro Rozas-Moreno, Rebeca Reyes‐García, Esteban Jódar-Gimeno, Mariela Varsavsky, Inés Luque-Fernández, María Cortés Berdonces, Manuel Muñoz‐Torres · 2017 · Endocrinología Diabetes y Nutrición (English ed )
  9. Effect of dipeptidyl peptidase‐4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus
    Young Choi, Seung‐Hyun Ko, Kiyuk Chang, Ki‐Dong Yoo, Sang‐Hyun Ihm · 2023 · Journal of Diabetes
  10. Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold
    Kelly A. Teske, Ganesha Rai, Premchendar Nandhikonda, Preetpal Singh Sidhu, Belaynesh Feleke, Anton M. Simeonov, Adam Yasgar, Ajit Jadhav, David J. Maloney, Leggy A. Arnold · 2017 · ACS Combinatorial Science
  11. Falls and fracture risk assessment—The role of osteoporosis, obesity, and sarcopenia
    Neema K. Sharda, Cathleen S Colon-Emeric · 2022 · Elsevier eBooks
  12. Obesity, Diabetes, and Fractures
    Melissa Orlandin Premaor, Juliet Elizabeth Compston · 2013 · Elsevier eBooks
  13. Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use
    MARK W. STOLAR · 2009 · Clinical Medicine Therapeutics
  14. Can Modeling of Health Outcomes Facilitate Regulatory Decision Making?: The Benefit–Risk Tradeoff for Rosiglitazone in 1999 vs. 2007
    James T. Cross, David Leroy Veenstra, Jacqueline S. Gardner, Louis P. Garrison · 2011 · Clinical Pharmacology & Therapeutics
  15. Risk Factors for Fracture in Diabetes: The Canadian Multicentre Osteoporosis Study
    Lisa-Ann Fraser, Αλεξάνδρα Παπαϊωάννου, Jonathan Derrick Adachi, Jinhui Ma, Lehana Thabane · 2013 · ISRN Epidemiology
  16. Improving cardiovascular risk - applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes
    Miles Fisher · 2009 · International Journal of Clinical Practice
  17. Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects
    Renata Bocciardi, Roberto Ravazzolo · 2010 · PPAR Research
  18. Skeletal consequences of thiazolidinedione therapy
    Jack L. Leahy · 2008 · Yearbook of Endocrinology
  19. Local and systemic functions of bone fat and its contribution to the energy metabolism--the effect of diabetes and obesity on bone.
    Beata Lecka‐Czernik · 2008 · PubMed
  20. Bone Biology and Effects of Pharmaceutical Intervention on Bone Quality
    Susan M. Ott · 2016 · Elsevier eBooks
  21. Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in insulin resistant c57bl/6 mice and in vitro studies.
    Chiara Cugno, Dhanya Kizhakayil, Rita Calzone, Shaikh Mizanoor Rahman, Ganesh V. Halade, Md. Tanvir Rahman · 2020 · Research Square
  22. Glitazones and Glitazars
    Miles Fisher · 2022
  23. Sclerostin deficiency sensitizes white adipocytes to thermogenic signals that induce beiging in mice
    Gillian M. Choquette, Soohyun P. Kim, Kevin J. Wilkinson, Belen Avelar, Sushrut M. Pathy, Zhu Li, Jasmine M. F. Wu, Susan M. Aja, Daniel L.J. Thorek, Michael J. Wolfgang et al. · 2026 · Nature Communications
  24. A simple fragility fracture risk score for type 2 diabetes patients: a derivation, validation, comparison, and risk stratification study
    Fengning Chuan, Youyuan Gao, Kun T. Liao, Xin Ye, Mei Mei, Wenqing Tian, Rong Li, Bo Zhou · 2023 · European Journal of Endocrinology
  25. PPARγ (peroxisome proliferator-activated receptor gamma) receptor in diabetes mellitus
    Radhika Sood, Akash Kumar Mourya, Ashutosh Kumar, Manish Kumar Jeengar · 2025 · Elsevier eBooks
  26. Global and regional prevalence of osteoporosis in kidney transplant recipients: a systematic review and meta-analysis
    Mobin Ghazaiean, Tahoora Mousavi, Mahmood Moosazadeh · 2025 · Clinical and Experimental Medicine
  27. Bone Disease, Gestational Diabetes Mellitus, and Health Care
    Zachary T. Bloomgarden · 2009 · Diabetes Care
  28. Orale Antidiabetika 2009
    Silvia Schwab, Peter Diem · 2009 · Therapeutische Umschau
  29. Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea
    Lúcio Vilar, Amaro Gusmão, José Luciano Albuquerque, Lisete Pontes, Larissa Montenegro, Soraya Pontes, George Robson Ibiapina, Rodrigo Andrade Cunha, Gercivan dos Santos Alves, Viviane Canadas et al. · 2011 · Arquivos Brasileiros de Endocrinologia & Metabologia
  30. Impact of Anti-hyperglycemic Medications on Bone Health
    Naim M. Maalouf · 2015 · Clinical Reviews in Bone and Mineral Metabolism
  31. Treating Type 2 Diabetes Mellitus
    Susan Herzlinger, Martin J. Abrahamson · 2009 · Springer eBooks
  32. Investigations of Diabetic Bone Disease
    Jakob Starup‐Linde · 2016
  33. Skeletal consequences of thiazolidinedione therapy
    J.L. Leahy · 2008 · Yearbook of Medicine
  34. What's Next for Diabetes Prevention?
    Steven E. Kahn, Kristina M. Utzschneider · 2011 · Diabetes Care
  35. Diabetes, diabetic medications, and risk of fracture
    Luca D’Onofrio, Andrea Palermo, Nicola Napoli · 2020 · Elsevier eBooks
  36. An integrated drug repositioning analysis identifies rosiglitazone as a treatment for sarcopenia
    Liang Shuang, Yong Liu, Hong‐Mei Xiao, Hong‐Wen Deng · 2026 · Communications Biology
  37. Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Melanie Jane Davies, Vanita R. Aroda, Mandeep Singh Bajaj, Nuha A. ElSayed, Francesco Giorgino, Jennifer Green, Rita Rastogi Kalyani, Nisa M. Maruthur, Chantal Mathieu, Sylvia E. Rosas et al. · 2026 · Diabetologia
  38. Correlates of fractures in elderly, diabetic outpatients
    Morgane Snacken, Laurent Crenier, Françoise Féry, J P Praet, Thierry Pepersack · 2015 · Acta Clinica Belgica
  39. Osteoporosis secundaria: diabetes mellitus e hipertiroidismo
    Manuel Muñoz‐Torres, Mariela Varsavsky, Antonia García Martín, F. Escobar‐Jiménez · 2010 · Medicine - Programa de Formación Médica Continuada Acreditado
  40. Ostéoporose induite par les antidiabétiques
    Marie‐Hélène Lafage‐Proust · 2011 · Revue du Rhumatisme Monographies
  41. iBAT on Bone
    Yihong Wan · 2013 · Endocrinology
  42. Rosiglitazone: how should we be using this oral hypoglycaemic drug after studies indicating increased MI risk have resulted in changes in recommendations?
    Brian Karet · 2008 · Primary Care Cardiovascular Journal (PCCJ)
  43. Diabetes clinical decision-making in patients at risk: Taking patient complexity into account
    F. Lavernia · 2013 · Osteopathic Family Physician
  44. Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
    Rupa Ahluwalia, Jiten P Vora · 2012 · The British Journal of Diabetes
  45. Pharmacothérapie du diabète de type 2
    William Harper, MAUREEN A. CLEMENT, Ronald Goldenberg, Amir Hanna, Andrea Main, Ravi R. Retnakaran, Diana Sherifali, Vincent C. Woo, Jean‐François Yale · 2013 · Canadian Journal of Diabetes
  46. Weighing the Potential Benefits and Risks of Antidiabetic Agents in Older Adults
    Joshua J. Neumiller, Peggy Soule Odegard, Stuart T. Haines · 2012 · Diabetes Spectrum
  47. Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease
    Sang Hoon Park · 2014 · Korean Journal of Medicine
  48. Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly
    Susan LaRue, Steven C. Brunell, Mary Beth DeYoung, Laura B. Hieronymus, Edward Bezarro, Steve Chen · 2013 · Diabetes Spectrum
  49. Mechanism for the Development of Bone Disease in Diabetes: Abnormal Glucose Metabolism
    Ryo Okazaki, Daisuke Inoue · 2016 · Springer eBooks
  50. Empirical Analysis of Socio-economic Factors Effecting Nutritional Status of Children (1-5) of Age
    Naima Saeed, Shumaila Kamal Khan, Hafiz Muhammad Raheed, Muhammad Zahid Hussain · 2018 · International Journal of Civic Engagement and Social Change
  51. Antidiabetic drugs and their effect on bone
    Peter Jackuliak, Martin Kužma, Juraj Payer · 2017 · Vnitřní lékařství
  52. The Effect of Glucovance Therapy on Biomechanical Deterioration of Bone in Streptozotocin-Induced Diabetic Rats
    Can Demirel · 2019 · Acta Endocrinologica (Bucharest)
  53. Bone and Diabetes
    Jakob Starup‐Linde, Søren Gregersen · 2018 · Endocrinology
  54. 277
    Banu Avcioglu Yilmaz, Füsun Baloş Törüner · 2013 · CRC Press eBooks
  55. Ostéoporose et diabète
    Martine Esther Cohen-Solal, Marie Christine de Vernejoul, Philippe Orcel · 2009 · Médecine & longévité
  56. Women in Clinical Drug Trials: United States Food and Drug Administration Update on Policies and Practices
    Ameeta Parekh · 2012 · KARGER eBooks
  57. Bone and Diabetes
    Jakob Starup‐Linde, Søren Gregersen · 2019 · Endocrinology
  58. Impact of glucose-lowering medications on bone health in diabetes
    Palak U. Choksi, MengHee Tan · 2020 · Elsevier eBooks
  59. An Overview of Sex and Gender in Pulmonary and Critical Care Medicine
    Shannon Kay, Margaret A. Pisani · 2021 · Clinics in Chest Medicine
  60. Bone and Diabetes
    Jakob Starup‐Linde, Søren Gregersen · 2018 · Endocrinology
  61. Chapter 60. Osteoporosis: Other Secondary Causes
    Neveen A. T. Hamdy · 2008 · Primer on the metabolic bone diseases and disorders of mineral metabolism
  62. Current Antidiabetic Therapies and Mechanisms
    Minghan Wang · 2011
  63. Secondary Osteoporosis: Other Causes
    Neveen A. T. Hamdy · 2013 · Primer on the metabolic bone diseases and disorders of mineral metabolism
  64. Comment identifier les sujets âgés à risque de fracture éligibles à un traitement ?
    J. Lorthiois, Valerie Skowronski, M. Fleury, Jean Bernard Gauvain · 2010 · Les cahiers de l année gérontologique
  65. Manifestaciones musculoesqueléticas de la diabetes mellitus
    M.-A. Timsit · 2008 · EMC - Aparato Locomotor
  66. Serum sclerostin concentration reflects bone turnover and glycation in men with type 2 diabetes mellitus
    Eisuke Tomatsu, Megumi Shibata, Yasumasa Yoshino, Sahoko Sekiguchi-Ueda, Ayako Kakita, Takeshi Takayanagi, Masaki Makino, Nobuki Hayakawa, Atsushi Suzuki · 2018 · Institutional Repositories DataBase (IRDB)
  67. NON-TRAUMATIC FRACTURES IN INDIVIDUALS WITH DIABETES
    Lisa-Ann Fraser · 2011 · MacSphere (McMaster University)
  68. Suppression of Osteoblast Phenotype in Marrow Mesenchymal Stem Cells by Nuclear Receptor PPARgamma2
    Sima Rahman · 2011
  69. Update Typ-2-Diabetes anhand ausgewählter aktueller Publikationen
    Monika Kellerer · 2009 · Der Diabetologe
  70. Diabetes Mellitus, Bone and Kidney
    Thomas E. Neumann, Gabriele Lehmann · 2012
  71. Improving Insulin Sensitivity: A Review of New Therapies
    Mary K. Rhee, Guillermo E. Umpierrez · 2008 · Clinical cornerstone
  72. Rosiglitazone induces osteoblasts apoptosis via PPARγ-GSK3β pathway
    Hui Sheng, Ge Zhang, Wenjun Li, Chunjun Sheng, Xiaoyun Cheng, Yongchun Yu, Hongfu Wang, WU Guo-ting, Ling Qin, Shen Qu · 2010 · Bone
  73. More Fat, Less Bone? Flame Retardant May Deliver a One–Two Punch
    Wendee Nicole · 2014 · Environmental Health Perspectives
  74. Les thiazolidinediones : des antidiabétiques avec des effets osseux
    Françoise Debiais · 2009 · Revue du Rhumatisme
  75. STATEmENT by AN Am ERICAN A SSOCIATION O f Cl INICA l E NDOCRINO l O g ISTS / Am ERICAN C O ll E g E O f E NDOCRINO l O gy C ONSENS u S PANE l ON Ty PE 2 D IA b ETES mE ll IT u S : A N Alg ORIT hm f OR g ly CE m IC C ONTRO l
    Helena W. Rodbard, Paul S. Jellinger, Jaime A. Davidson, DANIEL F. EINHORN, Alan J. Garber, George Grunberger, Yehuda Handelsman, Edward S. Horton, Harold E. Lebovitz, Philip T. Levy et al. · 2009
  76. Osteoporose bei Diabetes mellitus
    Martin Thomas Gaugg, Christian Heinz Anderwald, Elke Böttcher, Hans-Joerg Neumann · 2015 · Journal für Kardiologie (Krause & Pachernegg GmbH)
  77. Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea Eficácia da adição de vildagliptina ao tratamento de pacientes diabéticos não responsivos à combinação de metformina e uma sulfonilureia
    Lúcio Vilar, Amaro Gusmão, José Luciano Albuquerque, Lisete Pontes, Larissa Montenegro, Soraya Pontes, George Robson Ibiapina, Rodrigo Andrade Cunha, Viviane Canadas, Lúcia Helena et al. · 2011
  78. Bone and adipose tissue - more and more interdependence Kość a tkanka tłuszczowa - coraz więcej zależności
    Joanna Dytfeld · 2014
  79. AACE/ACE Consensus Statement
    George Grunberger, Jill M. Abelseth, Timothy Silleck Bailey, Bruce W. Bode, Yehuda Handelsman, Richard Hellman, Wendy S. Lane, Philip Raskin, William V. Tamborlane, Caitlin Rothermel · 2014
  80. Non-insulin therapy of type 2 Diabetes Mellitus:
    Zélia Lopes · 2010
  81. Treatment with Thiazolidinediones
    Seda Suvag, Kristina M. Utzschneider, Steven E. Kahn · 2013 · Springer eBooks
  82. Using AHRQ’s Evidence-Based Reports to Improve Managed Care Pharmacy Practice: Oral Antidiabetic Agents
    Kai Yeung · 2011 · Journal of Managed Care Pharmacy
  83. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
    B.L. Clarke · 2010 · Yearbook of Endocrinology
  84. ReviewArticle PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities
    David V. Erbe, James F. Tobin · 2008
  85. Bone and adipose tissue – more and more interdependence
    Joanna Dytfeld · 2014 · Reumatologia/Rheumatology
  86. The Effects of Diabetes and Obesity on the Skeleton
    Jessica R. Furst, John Paul Bilezikian, Mishaela Ruth Rubin · 2015 · Springer eBooks
  87. Review Article Cellular and molecular effects of thiazolidinediones on bone cells: a review
    Guillaume Mabilleau, Daniel Chappard, Michel Félix Baslé · 2011
  88. Diagnosis a nd Management of Osteoporosis
    Robert W. Lash, Jane M. Nicholson, Lourdes Vélez · 2009
  89. Glucose Control Medications
    Louise Mallet · 2016 · Springer eBooks
  90. Managing the Broad Spectrum of Type 2 Diabetes
    Evelyne Fleury‐Milfort · 2012 · Elsevier eBooks
  91. Thiazolidinediones and Fracture Risk in Diabetic Women
    Apn Cnp Diane E. Judge · 2008 · Journal watch
  92. Tratamiento de la diabetes mellitus (II). Hipoglucemiantes no insulínicos
    Francisco Javier Ampudia‐Blasco, Eva Perelló-Camacho · 2016 · Medicine - Programa de Formación Médica Continuada Acreditado
  93. Rola osteoprotegeryny w modulowaniu powstawania miażdżycy i możliwość wykorzystania jej oznaczenia w celu stratyfikacji ryzyka sercowo-naczyniowego
    Łukasz Jerzy Krzych, Maciej Tomasz Wybraniec · 2012 · Via Medica Journals
  94. Diabetic Bone Marrow & Stem Cell Dysfunction
    Meghan A. Piccinin · 2015 · Scholarship@Western (Western University)
  95. Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
    Da Young Lee, Ji A Seo · 2017 · Diabetes & Metabolism Journal
  96. Einfluss oraler Antidiabetika auf Knochenstoffwechsel und Frakturrisiko
    Cyril Traechslin, Janina Vavanikunnel, MARIUS E. KRAENZLIN, Christian Meier · 2018 · Osteologie/Osteology
  97. Guía práctica para la evaluación y el tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales
    Rebeca Reyes‐García, Esteban Jódar Gimeno, Antonia García Martín · 2014 · Elsevier eBooks
  98. Bone and Diabetes
    A. Palermo, A. Naciu, G. Tabacco, L. D'Onofrio, N. Napoli · 2018 · Springer eBooks
  99. Impact of Socioeconomic Factors on the Nutritional Status of Elementary School's Children in Rural Areas of Karachi (Pakistan)
    Naima Saeed, Tansif Ur Rehman, Mehmood Ahmed Usmani · 2018 · International Journal of Civic Engagement and Social Change
  100. Diabetes and Fracture Risk
    Serge Ferrari, Nicola Napoli, Ann V. Schwartz · 2018 · Primer on the metabolic bone diseases and disorders of mineral metabolism